Production (Stage)
Enzon Pharmaceuticals, Inc.
ENZN
$0.0852
-$0.0058-6.37%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 208.31% | -7.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 208.31% | -7.41% | |||
| Operating Income | -208.31% | 7.41% | |||
| Income Before Tax | -328.51% | -27.06% | |||
| Income Tax Expenses | -93.52% | 497.96% | |||
| Earnings from Continuing Operations | -627.78% | -128.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -627.78% | -128.35% | |||
| EBIT | -208.31% | 7.41% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -530.30% | 189.19% | |||
| Normalized Basic EPS | -326.32% | -26.92% | |||
| EPS Diluted | -530.30% | 189.19% | |||
| Normalized Diluted EPS | -326.32% | -26.92% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||